Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Open Access
- 1 June 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (6) , 814-820
Abstract
Gastrointestinal stromal tumors (GISTs) arise predominantly in the muscularis mucosa of the gastrointestinal tract, of which most contain activating mutations in V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) (OMIM 164920), which encodes a transmembrane tyrosine kinase. A few GISTs (5%-10%) contain activating mutations in the platelet-derived growth factor receptor α (PDGFRA) (OMIM 173490) gene; the most common PDGFRA mutation is in exon 18, resulting in a change in residue 842 from aspartic acid to valine (D842V).1,2 Those GISTs that lack mutation in KIT or PDGFRA frequently have loss of the succinate dehydrogenase (SDH) complex through mutation of a gene that encodes 1 of the subunits or epigenetic regulation that affects gene expression.3 The initial treatment for patients with unresectable, recurrent, or metastatic GISTs is imatinib mesylate based on drug activity, drug tolerability, and long-term control of GISTs in randomized clinical trials.4-6 Patients with GISTs that are primary refractory to imatinib frequently have mutations in KIT or PDGFRA within an exon that renders the protein less sensitive to inhibition of kinase activity by imatinib or unmutated (wild-type) KIT and PDGFRA.1 In patients whose GISTs initially respond to imatinib but later progress during treatment, secondary mutations in KIT frequently occur and contribute to the development of resistance.7Keywords
This publication has 29 references indexed in Scilit:
- Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain MutationsPLOS ONE, 2013
- Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III studyClinical Pharmacology: Advances and Applications, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinibAnnals of Oncology, 2012
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinibCancer Chemotherapy and Pharmacology, 2011
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2008
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958